90% of drugs fail in development. We take a look at the stumbles, blow-ups and near-misses of the experimental drugs that didn't make the cut.
The biggest biopharma industry conference of the year. A three-day event hosted by Endpoints alongside coverage of JPM: Wall-to-wall news stories, coverage via our event in San Francisco featuring in-person and online panels on the upcoming trends in biopharma with a focus on dealmaking, regulation coming from Washington, drug pricing, pipelines and more.
All the news from the biggest healthcare investor conference of the year — covered by the Endpoints team in real time.
What do analysts project to be the next big blockbuster products coming from R&D pipelines? Last year, this report highlighted the industry's biggest gamble — Biogen's Alzheimer's drug aducanumab. While the drug ended in failure, the story was one of the industry's biggest conversations all year.
The biopharma VC world's most prolific dealmakers, ranked by number of deals and the dollars they put to work. Featuring an interactive data set.
By all accounts, 2022 was a gut-wrenching year for biotech investors. The IPO window closed, after years of a free-for-all, and funding requirements grew bigger and longer for startups while valuations changed. So what did we learn about rounds and technology after crunching the numbers on one of the most popular lists at Endpoints News? Join editor-in-chief John Carroll and his panel of VC insiders for a round-table discussion about what lies ahead for biotech.
The next class of mRNA tech is poised to provide for a wide range of applications — but what exactly does the immediate future hold? Our expert panel will break down the latest mRNA products in development and find out where the technology is headed.
The next class of mRNA tech is poised to provide for a wide range of applications — but what exactly does the immediate future hold? Our expert panel will break down the latest mRNA products in development and find out where the technology is headed.
All the news out of the American College of Cardiology annual meeting, covered by the Endpoints team in real time.
Our semi-annual survey of CEOs & industry executives highlighting what’s top of mind for these leaders during the first half of the year. We survey our exclusive group, analyze their comments and use it to share where insiders think the industry is headed and what it cares about most.
R&D is the lifeblood of biopharma, but it doesn't come cheap. We break down the biggest spenders on research and development, and look at what they got in return for the bets they put on the table. Data and analysis of the industry's most important investment.
Last fall at ESC it became apparent that big cardio diseases are back in vogue. Merck’s picked up on this by making cardio a top growth sector in the pipeline. And we’ve been seeing a surge in new R&D projects. All this after big costs and low success rates forced a rethink in Big Pharma. What’s happening now to inspire such a big change? Lei Lei Wu is digging in.
Last fall at ESC it became apparent that big cardio diseases are back in vogue. Merck’s picked up on this by making cardio a top growth sector in the pipeline. And we’ve been seeing a surge in new R&D projects. All this after big costs and low success rates forced a rethink in Big Pharma. What’s happening now to inspire such a big change? Lei Lei Wu is digging in.
All the news from the American Association for Cancer Research conference in Orlando, Florida. This is an R&D-focused conference that always generates a handful of major headlines on the drugs of tomorrow.
The top news out of AACR delivered to our audience in a single email issue.
An Endpoints Day focused on drug discovery, featuring a panel session hosted by an Endpoints journalist with more sessions to be announced. This event will focus on research pipelines, emerging drug targets and the inflection point of research to development.
The people who turn drugs into blockbusters: Endpoints profiles the marketing leaders with the most influence in the industry.
Coming soon
CAR-T therapy is best known for cancer care — and outcomes that have seen life-changing results making headlines. But what’s next? All signs point to autoimmune disease as the target on the horizon. Senior Editor Amber Tong and a panel of experts will examine the promising early clinical data and break down challenges that lie ahead.
Moderator: Amber Tong
Who made the biggest gambles with their M&A bets? This data-driven list looks at the biggest deals on experimental products that could turn into booms or busts.
Editor: John Carroll
The cell & gene landscape is ripe with big promises backed by evolving tech, fresh talent with splashes of funding and M&A catching headlines as therapies roll forward. But how are the experts doing it in 2023? What are the biggest scientific advancements — and best strategies for investment, manufacturing and commercial access? Join us as we explore the field’s future — and examine past safety issues — with a series of sessions geared toward furthering cell & gene drug development.
Topic details coming soon
The future leaders of biotech — many of whom are already reaching for the top of their game. These are the 20 executives under 40 who are making an impact on the industry, have raised serious capital, or are moving innovative, exciting companies forward.
A preview of what’s to come at BIO, delivered to our audience in a single email issue.
The most anticipated cancer conference of the year, with practice-changing clinical data and a large corporate presence eyeing one of the biggest categories of drug R&D and commercial sales. We have a team on the ground covering the hottest news out of ASCO.
What data are making the biggest waves at ASCO? Our slate of sessions include an expert roundtable, fireside and more. Join us as we analyze the most anticipated cancer conference of the year.
The top news out of ASCO delivered to our audience in a single email issue.
The biotech industry’s annual trade conference is back in Boston. We assess where we are as an industry and break down the future trends in biopharma. Featuring conversations on dealmaking, pipeline trends, biotech funding, and more — plus a focus on what the mid-year outlook holds.
Our special report profiles the achievements of LGBTQ+ biopharma execs and scientific leaders who are influencing the industry.
Cannes has become one of the big hub events for media, marketing and advertising. We report on the marketing deals and trends that will drive how drugs are advertised and sold to patients.
The US Federal Trade Commission and other global regulators have stepped up antitrust enforcement in life sciences, most notably seeking to unwind Illumina's $8 billion buyout of Grail. Other acquisitions, led by Amgen and Pfizer, have run into review or scrutiny. Endpoints News will examine the origins, impacts and likely legacy of these antitrust policies.
The top news out of Cannes Lions delivered to our marketing audience in a single email issue.
The political issues circling the FDA this year could potentially ripple into biopharma on a scale that’s never been seen before. All eyes are on the FDA’s response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints’ Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We’ll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.
90% of drugs fail in development. We take a look at the stumbles, blow-ups and near-misses of the drugs that didn't make the cut.
An Endpoints Day focused on drug commercialization, featuring a panel hosted by an Endpoints journalist with more sessions to be announced. This event will focus on trends in drug launches, marketing and sales.
Who are the women leading and influencing biopharma? Each year we seek out the up-and-comers moving the industry forward. Our in-depth profiles establish their stories into the fabric of an industry that isn’t changing fast enough to keep up with gender diversity.
A spotlight on the women leading and influencing biopharma in 2023. Join us as we bring the award celebration to a live audience. We’ll gather a group of industry leaders to discuss the way forward to push gender equality to reality.
Topic details coming soon
As science has enabled care for previously untreatable, ultra-rare conditions, health systems and governments are struggling with ways of financing research and development of these therapies. What are the solutions when the science has progressed, but the economics haven't?
An Endpoints Day focused on drug manufacturing, featuring a panel hosted by an Endpoints journalist with more sessions to be announced. We'll focus on the latest news and trends in drug supply chains, manufacturing developments and how the post-pandemic environment is affecting long-term capital expenditure planning.
Topic details coming soon
UC San Diego recently launched a new astrobiotechnology hub, but one of the efforts pushing drug development and manufacturing into space. After early experiments, researchers are now launching into the cosmos with more tangible aims, like refining drug targets and building better manufacturing technology.
Writer:Lei Wu
The European Society of Cardiology — practice-changing research is revealed along with clinical updates to drugs in development. Endpoints is there in person covering the news as it breaks real time in Amsterdam.
Our semi-annual survey of CEOs & industry executives highlighting what’s top of mind for these leaders during the first half of the year. We survey our exclusive group, analyze their comments and use it to share where insiders think the industry is headed and what it cares about most.
Profiles of the top 11 private biotechs in pursuit of new drugs and who are pushing the envelope with powerful new technologies.
The Endpoints 11 — awarding the top private biotechs in pursuit of new drugs and who are pushing the envelope with powerful new technologies.
Topic details coming soon
A new US law permits US drugmakers to obtain early safety data using alternatives to animal testing, such as computer modeling and "organ-on-a-chip" technology. Scientific advancements, policy changes and evolving views may herald a new era of drug testing. Endpoints News will take a look at the promise and limitations of these technologies.
Where is cancer drug R&D is headed now — what are the new types of tech and targets making waves? What’s on the horizon for the latest cancer drugs in development?
Charting the waters ahead for drug development in Europe — a day-long series of sessions on financing, R&D trends and regulatory issues that are central to the industry.
Europe’s headlining cancer conference lands in Madrid this year as major medical updates on drugs in the pipeline are given out. Endpoints covers the readouts in real time.
The top news out of ESMO delivered to our audience in a single email issue.
Our event on the ground at ESMO — we break down what drugs in the cancer pipeline are the ones to watch, and which ones didn’t make it past the goal line. Join our expert panel, fireside chat and more.
CPhI brings together members of the drug supply chain, including many of the critical pharma service companies that drive the supply and production of drugs. We cover it this year via our weekly Manufacturing Report.
The top news out of CPhI delivered to our manufacturing audience in a single email issue.
Topic details coming soon
Topic details coming soon
An Endpoints Day focused on clinical trials, featuring a panel session hosted by an Endpoints journalist and more. What are the latest trends in clinical trials? What regulatory curves are making the biggest waves? We’ll also take a look at how expectations from the industry and beyond are shifting the trial strategies of the future.
The 10 stories that Endpoints readers connected with most in 2023. They're the stories with the biggest impact, the largest readership, and that were key milestones for where the industry went this year.
Topic details coming soon
Topic details coming soon
The Endpoints team will be on the ground to bring drug updates out of ASH this year — will some of the most coveted cell & gene therapy readouts take center stage?
ASH’s focus on blood cancers and disorders provide the battleground for some of the most coveted cell & gene therapy readouts. The Endpoints team will take apart and piece together the data with a panel of experts followed by a fireside chat.
The top news out of ASH delivered to our audience in a single email issue.